AD80, a multikinase inhibitor, exhibits antineoplastic effects in acute leukemia cellular models targeting the PI3K/STMN1 axis

Cytoskeletal Proteins in Cancer and Intracellular Stress: A Therapeutic Perspective

(2020) Mei Shan Ong et al.   Cancers

Acute lymphoblastic leukaemia

(2020) Florent Malard et al.   LANCET

The unfolded protein response modulators GSK2606414 and KIRA6 are potent KIT inhibitors

(2019) Mohamed Mahameed et al.   Cell Death & Disease

Phenotype-based screens with conformation-specific inhibitors reveal p38 gamma and delta as targets for HCC polypharmacology

(2019) Jia Xin Yu et al.   MOLECULAR CANCER THERAPEUTICS

Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors

(2017) Dennis Plenker et al.   Science Translational Medicine

Acute lymphoblastic leukemia: a comprehensive review and 2017 update

(2017) T Terwilliger et al.   Blood Cancer Journal

Pharmacologic Targeting of S6K1 in PTEN-Deficient Neoplasia

(2017) Hongqi Liu et al.   Cell Reports

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

(2016) D. A. Arber et al.   BLOOD

Overexpression of gelsolin reduces the proliferation and invasion of colon carcinoma cells

(2016) Wen-Xiang Li et al.   Molecular Medicine Reports

Molecular effects of the phosphatidylinositol-3-kinase inhibitor NVP-BKM120 on T and B-cell acute lymphoblastic leukaemia

(2015) João Kleber Novais Pereira et al.   EUROPEAN JOURNAL OF CANCER

Comprehensive characterization of the Published Kinase Inhibitor Set

(2015) Jonathan M Elkins et al.   NATURE BIOTECHNOLOGY

Acute Myeloid Leukemia

(2015) Hartmut Döhner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Stathmin 1 inhibition amplifies ruxolitinib-induced apoptosis in JAK2V617F cells

(2015) João Agostinho Machado-Neto et al.   Oncotarget

Stathmin 1 in normal and malignant hematopoiesis

(2015) Joao Agostinho Machado-Neto et al.   BMB Reports

C-KIT Signaling in Cancer Treatment

(2014) Karmen Stankov et al.   CURRENT PHARMACEUTICAL DESIGN

Stathmin 1 is involved in the highly proliferative phenotype of high-risk myelodysplastic syndromes and acute leukemia cells

(2013) João Agostinho Machado-Neto et al.   LEUKEMIA RESEARCH

Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

Discovery of 7-Methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a Potent and Selective First-in-Class Inhibitor of Protein Kinase R (PKR)-like Endoplasmic Reticulum Kinase (PERK)

(2012) Jeffrey M. Axten et al.   JOURNAL OF MEDICINAL CHEMISTRY

Chemical genetic discovery of targets and anti-targets for cancer polypharmacology

(2012) Arvin C. Dar et al.   NATURE

Stathmin: a protein with many tasks. New biomarker and potential target in cancer

(2011) Barbara Belletti et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

GDP366, a novel small molecule dual inhibitor of survivin and Op18, induces cell growth inhibition, cellular senescence and mitotic catastrophe in human cancer cells

(2010) Xianping Shi et al.   CANCER BIOLOGY & THERAPY

Conformer Generation with OMEGA: Algorithm and Validation Using High Quality Structures from the Protein Databank and Cambridge Structural Database

(2010) Paul C. D. Hawkins et al.   Journal of Chemical Information and Modeling

Clinical Utility of Microarray-Based Gene Expression Profiling in the Diagnosis and Subclassification of Leukemia: Report From the International Microarray Innovations in Leukemia Study Group

(2010) Torsten Haferlach et al.   JOURNAL OF CLINICAL ONCOLOGY

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

(2009) H. Dohner et al.   BLOOD